Managing hemophilia treatment is a complex task and the bleeding disorder, though rare, can be a major cost driver for employer-sponsored health plans. Yet employers can take immediate steps — from exploring site-of-care options to regularly gathering meaningful data — to better contain pharmaceutical costs that represent upwards of 90% of the total cost of care.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.